Skip to main content

Table 2 Expected and observed frequencies, related risk of occurrence of malignancies of different site of origin in psoriasis families

From: Psoriasis vulgaris and familial cancer risk- a population-based study

Tumor site Gender Observed cases Expected cases Relative risk (RR, CI 95%), p
Breast Females 20 21 1.0, p= 0,8736
Lungs Males 26 26 1.0, p=1.0
Females 13 9 1,2, p=0,3891
Colorectal Males 15 16 1.0, p=0,8553
Females 9 11 0.9, p=0,6518
Stomach Males 5 6 0.9, p=0,7618
Females 4 10 0.6, p=0,1066
Liver Males 1 1 1.0, p=1.0
Females 2 1 1.3,p=0,5632
Melanoma Males 2 2 1.0, p=1.0
Females 5 2 1.4, p=0,2554
Kidney Males 4 5 0.9, p=0,7378
Females 6 4 1.2, p=0,5253
Prostate Males 15 16 1.0, p=0,8553
Larynx Males 6 3 1.3, p=0,3152
Females 1 0,5 1.3, p=0,1964
CNS Males 3 2 1.2, p=0,6539
Females 4 2 1.4, p=0,4130
Leukaemia Males 5 2 1.4, p=0,2552
Females 5 2 1.4, p=0,2554
Hodgkin Lymphoma Males 2 0,2 1.8, p=0.002*
Females 0 0 -
Bones Males 1 1 1.0, p=1.0
Females 2 1 1.3, p=0,5632
Bladder Males 1 1 1.0, p=1.0
Females 0 2 P=0,1569
NHL Males 1 1 1.0, p=1.0
Females 1 1 1.0, p=1.0
Pancreas Males 2 3 0.8, p=0,6539
Females 3 3 1.0, p=1.0
Uterus Females 3 7 0.6, p=0,2039
Ovary Females 4 5 0.9, p=0,7379
Thyroid Males 0 0.5 P=0.0523
Females 2 2 1.0, p=1.0
Cervix Females 5 4 1.1, p=0,7379
Non-melanoma skin cancer Males 9 9 1.0, p=1.0
  Females 9 8 1.0, p=0,8069
  1. *p-after Bonferroni correction.